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Abstract
Background: Epigenetic information can be used to identify clinically relevant genomic variants single nucleotide
polymorphisms (SNPs) of functional importance in cancer development. Super-enhancers are cell-specific DNA
elements, acting to determine tissue or cell identity and driving tumor progression. Although previous approaches
have been tried to explain risk associated with SNPs in regulatory DNA elements, so far epigenetic readers such as
bromodomain containing protein 4 (BRD4) and super-enhancers have not been used to annotate SNPs. In prostate
cancer (PC), androgen receptor (AR) binding sites to chromatin have been used to inform functional annotations of SNPs.
Results: Here we establish criteria for enhancer mapping which are applicable to other diseases and traits to achieve the
optimal tissue-specific enrichment of PC risk SNPs. We used stratified Q-Q plots and Fisher test to assess the differential
enrichment of SNPs mapping to specific categories of enhancers. We find that BRD4 is the key discriminant of tissue-
specific enhancers, showing that it is more powerful than AR binding information to capture PC specific risk loci, and
can be used with similar effect in breast cancer (BC) and applied to other diseases such as schizophrenia.
Conclusions: This is the first study to evaluate the enrichment of epigenetic readers in genome-wide associations
studies for SNPs within enhancers, and provides a powerful tool for enriching and prioritizing PC and BC genetic risk
loci. Our study represents a proof of principle applicable to other diseases and traits that can be used to redefine
molecular mechanisms of human phenotypic variation.
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Background
Genome-wide association studies (GWASs) have linked
more than ten thousand of single nucleotide polymor-
phisms (SNPs) to human diseases and traits [1]. Given
that a great part of associated variants are located in
known tissue-specific enhancers, a recent study by
Tehranchi and colleagues [2] found that these non-coding
variants affect transcription factors (TFs) binding and
gene expression. Although they found that CCCTC-
binding factor (CTCF) is likely to play a pioneering role in
translating natural genetic variation in chromosomal
architecture [2], we still strive to understand tumor-
specific epigenetic features that render possible progression
toward such disease. For instance, previous approaches
have been adopted to explore disease risk association with
regulatory DNA elements [3–6].
In prostate cancer (PC) the androgen receptor (AR)
binds predominantly to gene-distal sites and has been
used by multiple groups to functionally annotate genetic
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risk loci based on overlaps with risk single nucleotide
polymorphisms (SNPs) as measured in genome-wide
association studies (GWAS), which in some cases are
also predicted to affect AR binding [7, 8].
Epigenetic marks such as acetylation on Histone 3
lysine 27 (H3K27ac) have been used as annotation of
enhancers [9]. Moreover, regions of extended H3K27ac
bound by combinations of mediator complex subunit 1
(MED1) and bromodomain containing protein 4 (BRD4)
have been defined as super-enhancers important to
determine cell identity [10–12]. BRD4 has proven to be
involved in several diseases thanks to the small molecule
inhibitor JQ1 [13]. In PC cells, BRD4 was recently
shown to bind to the AR and affect its activity [14] while
components of the mediator complex such as MED1
and MED12 were recently found to be implicated in
advanced PC [15, 16].
SNPs associated with common diseases have been
found to lie within enhancers driving transcriptional
output and have been identified using different
methods [9]. For PC, the most recent methods in-
clude genotyping matched to expression quantitative
trait loci analysis and epigenetic marks such as
H3K27Ac combined with chromatin accessibility [17,
18] or additional combination of binding information
for key TFs such as AR and FOXA1 [19]. Here we
combined information on H3K27ac profile with bind-
ing site data for BRD4 and MED12 to improve the
functional annotation of PC risk SNPs based on a
previously described enrichment analysis [18].
We show that this method is able to capture SNPs asso-
ciated not only with PC but also in the context of Breast
Cancer (BC) and Lung Cancer (LC) susceptibility. We find
that BRD4 is the key discriminant of tissue-specific super-
enhancers and binds disease specific PC and BC low
p-value risk SNPs. Enrichment of disease-specific risk SNPs
is higher when BRD4 binding profile information is incor-
porated with other epigenetic marks such as H3K27Ac and
MED components, than for binding profiles of key TFs im-
plicated in disease development and progression such as
the AR or estrogen receptor (ER). Inhibitors for
BRD4 are in clinical trials. However, little is known
about the contribution of BRD4 to brain diseases. In
order to evaluate if similar principles apply also for
heritable mental disorders we extended our frame-
work to epigenetic marks including BRD4 binding de-
rived from Schwann cells and applied the enrichment
analysis to GWAS studies of mental disorders from
the Psychiatric Genetics Consortium (PGC) [20, 21].
Methods
Data source for enhancers’ annotation
AR binding information in both LNCaP and VCaP cells
was retrieved from Massie et al., (2011) [22]. Raw data
were aligned with novoalign to human genome version
hg19, and peaks were called with MACS using default pa-
rameters after filtering low quality reads (score below 20).
Resulting peaks were then overlapped using Bedtools.
MED1 binding information and H3K27Ac profile in
LNCaP cells was retrieved from Wang et al., (2012) [23]
and re-analyzed as described above. To define the degree
of overlap with super-enhancers, we also downloaded
super-enhancers coordinates from dbSUPER database
[24]. BRD4 binding information and H3K27Ac profile in
VCaP cells was retrieved from Asangani et al., (2014) [14].
ER and BRD4 binding information were retrieved from
Nagarajan et al., (2014) [25]. H3K27Ac profile in MCF7
was retrieved from Theodorou et al., (2013) [26]. BRD4
and MED1 binding information, and H3K27Ac profile for
small cell lung cancer (SCLC) cell line H2171 and
Schwann cells were retrieved from cistrome [27]. All cell-
specific datasets were equally analyzed to ensure compar-
ability within a tissue type.
Enhancers were defined in LNCaP based on (1) ex-
tended H3K27Ac marked regions ranging from 3000 bp
to 200 kb (Additional file 1); (2) an intersection of these
H3K27Ac marked regions with MED12 binding sites
(Additional file 2). In VCaP cells enhancers were defined
(3) as an extended H3K27Ac marked regions ranging
from 3000 bp to 200 kb (Additional file 3) (4) the inter-
section of H3K27Ac stretches longer than 2000 bp and
BRD4 binding sites (in VCaP cultured in presence of an-
drogens) (Additional file 4) or (5) as BRD4 sites alone
(Additional file 5). (6) To achieve a consensus map of
super-enhancers in PC (Additional file 6) we selected
super-enhancers found in LNCaP cells that were found
to have H3K27Ac and BRD4 binding also in VCaP cells.
Enhancers in MCF7 cells were identified following the
criteria described in Hnisz et al., (2013) [12]. First,
H3K27Ac peaks closer than 100 bp were merged, then
only stretches longer than 2000 bp were selected
(Additional file 7). Different compendia of enhancers
were then created based on the presence of BRD4
(Additional file 8) and ER binding (Additional file 9) or
the combination of these features (Additional files 10
and 11). The same type of algorithm was followed to
identify enhancers in H2171 and Schwann cells 90-8TL
(Additional files 12, 13, 14, 15, 16, 17 and 18). DNase I
hypersensitive sites (DHS) profiles for LNCaP cells were
retrieved from He et al. (2012) [28] and from ENCODE
(Additional files 19 and 20). A more stringent profile of
these two based on overlap (Additional file 21) was also
included.
Data source for summary statistics of genome-wide
association studies
We obtained summary statistics from large meta-
analyses of the traits of interest. In particular, the
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summary statistics for association with PC risk were ob-
tained from the Illumina array Collaborative Oncological
Gene-environment Study (iCOGS) consortium [29] and
comprised information on 25,074 cases and 24,272 con-
trols genotyped on a customized array including 211,155
SNPs. Additionally, we used summary statistics on
525,821 SNPs for association with PC risk derived from
a smaller UK-based cohort including 1854 cases and
1854 controls in collaboration with the PRACTICAL
consortium [30]. Genetic association with BC risk was
obtained in collaboration with the BCAC consortium
and was derived from a meta-analysis including 15,863
cases and 40,022 controls on ~2.5 million SNPs [31].
We collected also summary statistics for 14,900 cases of
lung cancer (LC) and 29,485 controls including
2,433,836 SNPs from the TRICL consortium [32]. From
the IGAP consortium we obtained summary data from
17,008 Alzheimer's disease cases and 37,154 controls
genotyped on 518,871 SNPs [33]. Finally from the
PGC consortium we used summary statistics on asso-
ciation with schizophrenia on 36,989 cases and
113,075 controls including 2,540,803 SNPs [21], and
summary statistics on association with bipolar dis-
order on 11,974 cases and 51,792 controls on a total
of 2,382,073 SNPs [20].
SNPs enrichment method
Enrichment is defined by the presence of lower p-values
than expected by chance. Quantile-quantile (Q-Q) plots
are tools commonly used in genetics to visualize enrich-
ment [18]. Typically, the observed p-value quantiles on
the y-axes are plotted against the theoretical p-value
quantiles under the assumption of no association (i.e.
following the quantiles of the uniform distribution) on
the x-axes. In case of no association, a Q-Q plot follows
a straight 0–1 line starting from the origin. In the pres-
ence of association, the enrichment (of low p-values) is
described by the deflection of the Q-Q plot from this
theoretical line of no association. We used stratified Q-
Q plots to assess differential enrichment of SNPs map-
ping to specific categories of enhancers. Stratified Q-Q
plots have been used previously to demonstrate enrich-
ment of general location annotation categories such as
5’UTR SNPs [18].
Quantifying SNPs enrichment within sets of enhancers
To assess the significance of the association enrichment
among the sets of SNPs within enhancers we used
Fisher’s hypergeometric test. More specifically, we tested
for over-representation of genome-wide significant SNPs
(i.e. association of –log10 p-value > 7.3) within specific
enhancers. We adjusted for multiple testing using a
Bonferroni-correction accounting for the number of
annotations tested.
Random pruning
The statistical models underlying the SNP enrichment
analyses carried out here generally assume independence
of the data. Far from resembling independent samples,
SNPs are linked by complex correlation patterns
reflected in their linkage disequilibrium (LD) structure.
In order to adhere more closely to the independence as-
sumption, and to rule out bias due to confounding fac-
tors such as LD, and assess whether the intrinsic
capacity of functional annotations to enrich specific SNP
sets was due to such confounding factors, the SNPs were
randomly pruned prior to the analyses by randomly
selecting representatives from all 1Mbase LD blocks of
SNPs with pairwise r2 ≥ 0.2. Iterating the random prun-
ing procedure 100 times and subsequently averaging the
corresponding test statistics compensated the arbitrari-
ness in the choice of representative SNPs. These analyses
were performed and shown in Additional file 22: Figures
S1, S3, and S6.
Results
To assess whether tissue or cell-specific enhancers could
mark tissue-specific risk SNPs associated with develop-
ment of PC, we analyzed datasets from two studies that
profiled MED12 binding and H3K27Ac map in LNCaP
cells [23], and BRD4 and H3K27Ac in VCaP cells [14].
MED12, is a subunit of the same chromatin looping me-
diator complex as MED1 [34] therefore we used it for
our PC study assuming that these two subunits would
have similar binding profiles in the same cells.
Enhancers were defined in LNCaP based on (1) ex-
tended H3K27Ac marked regions (Additional file 1); (2)
an intersection of these H3K27Ac marked regions with
MED12 binding sites (Additional file 2). In VCaP cells
enhancers were defined as (3) extended H3K27Ac
marked regions (Additional file 3) (4) the intersection of
H3K27Ac stretches and BRD4 binding sites (Additional
file 4) or (5) as BRD4 sites alone (Additional file 5). (6)
To achieve a consensus map of enhancers in PC
(Additional file 6) we intersected the enhancers found in
both LNCaP and VCaP cells characterized by all three
epigenetic features and responded to the definition of
super-enhancers [12] (Table 1 and Fig. 1).
Enrichment of SNPs associated with prostate cancer in
regions bound by MED and BRD4, marked by H3K27Ac in
prostate cancer cells
First, we overlaid genome coordinates of enhancers in
PC cell lines, as defined previously, with genomic coor-
dinates of all SNPs in the PC iCOGS dataset [29]. To
visualize differential enrichment patterns of specific epi-
genetic markers with respect to their genetic association
with PC risk we generated stratified Q-Q plots which is
a method for visualizing the enrichment of statistical
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association relative to that expected under the global
null hypothesis [18]. Q-Q plots show that SNPs within
regions with different genomic features (H3K27ac,
BRD4, and MED12, or a combination of these) had dif-
ferent enrichment patterns compared to all SNPs
(Fig. 2a). The SNPs contained in common PC enhancers,
and therefore characterized by BRD4 and MED12
binding, and a long stretch of H3K27Ac had lower p-
values than SNPs contained in enhancers identified in
VCaP cells by mapping long stretches of H3K27Ac
and BRD4 binding. SNPs associated with PC risk
were more enriched within BRD4 binding sites alone
than within H3K27Ac sites or H3K27Ac/MED12 over-
lapping sites in LNCaP. In addition, we focused on
SNPs achieving genome wide significance and com-
pared overrepresentation of these SNPs mapping to
the above-described enhancers (Additional file 22:
Table S1). 12% and 3% of the SNPs contained in PC
enhancers achieved genome-wide significance in the
iCOGS and in the PRACTICAL GWAS respectively.
SNPs that achieved significance in iCOGs are listed
in Additional file 22: Table S2. These results highlight
that combining generic epigenetic marks such as
H3K27Ac with generic epigenetic readers such as
BRD4 and with MED binding increases the capacity
of capturing SNPs associated with PC.
Importantly, to rule out possible confounding factors,
we first randomly pruned the SNPs, selecting one repre-
sentative SNP per LD block. The random pruning did
not change the enrichments patterns caused by the func-
tional annotations (Additional file 22: Figure S1).
Secondly, in order to rule out that the enrichment
merely results from the non-independence of the SNPs
in the enhancer regions or other confounding features of
these, we compared the observed enrichment to the one
attained on a set of SNPs numerically matching those in
the enhancer regions on minor allele frequencies and
mutual LD r2 (Additional file 22: Figure S2). The numer-
ically matched SNP set was also used as control set to
assess the enrichment significance (Additional file 22:
Table S1, S3, S4) by means of Fisher’s hypergeometric
test (see Methods).
Enrichment of prostate cancer associated SNPs within
androgen receptor binding information.
We also compared the genomic coordinates of the SNPs
to the coordinates for AR binding sites (ARBSs). Despite
the use in the literature of ARBSs for functional annota-
tion of GWAS significant PC SNPs, intersecting enhancer
information with AR binding data did not lead to any fur-
ther enrichment of SNPs associated with PC compared
with enhancer information alone (Fig. 2b and Additional
Table 1 SNPs mapping to epigenetic marks used to define enhancers in prostate and breast cancer
Cell line/Tumor
type
Epigenetic marks Key transcription
factora
Number of SNPs within the intervals covered by the array:
iCOGS PRACTICAL BCAC All
LNCaP H3K27Ac —— 1605 3092 13482 13503
AR 669 1274 5664 5671
LNCaP H3K27Ac +MED12 —— 685 1271 5428 5442
AR 279 541 2310 2316
VCaP H3K27Ac + BRD4 —— 587 983 4218 4239
AR 342 502 2148 2154
VCaP BRD4 —— 859 1595 7984 8066
AR 23 60 233 233
VCaP H3K27Ac —— 3896 8440 38150 38444
PC H3K27Ac +MED12 + BRD4 —— 82 130 618 619
AR 49 46 248 249
PC —— AR 496 1403 5950 5967
MCF7 H3K27Ac + BRD4 —— 8783 21058 93969 94858
ER 4296 10607 45937 46222
MCF7 H3K27Ac —— 19270 48028 215997 217382
ER 6710 16206 69743 70058
MCF7 BRD4 —— 280 495 2617 2641
ER 34 66 282 282
MCF7 —— ER 158 371 1638 1639
aBinding information for key transcription factors such as androgen receptor (AR) or estrogen receptor (ER) where used alone or in combination with the
epigenetic mark profiles in order to assess their capacity to refine enrichment of risk SNPs
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file 22: Table S3). In particular, although intersecting AR
binding information induced a slight left-shift of the Q-Q
plot for enhancers marked by H3K27Ac, MED12, and
BRD4 binding, and for enhancers marked by H3K27Ac
and BRD4, the enrichment was caused by the same SNPs
responsible for the enrichment without AR binding infor-
mation (see Additional file 22: Table S1 and S3). Further-
more, enhancer information outperformed ARBSs profile
alone, or in combination with H3K27Ac profile, in enrich-
ing for genome-wide significant p-valued SNPs in PC
(Additional file 22: Table S3), and overlapping AR with
BRD4 binding sites did not alter the superior capabil-
ity of BRD4 (as in Fig. 2a) to enrich for disease asso-
ciated SNPs. Interestingly, although DHSs have been
used to predict locations of common disease-
associated variation [3], DHSs profiles enriched less
than ARBSs alone (Additional file 22: Figure S3).
Validation of the enrichment method on an independent
GWAS for prostate cancer.
Finally, we validated our results on the independent PC
GWAS obtained from the PRACTICAL consortium
measured on a smaller UK-based cohort [30] (Fig. 2c).
Again, we observed the strongest SNP enrichment in PC
super-enhancers marked by H3K27Ac, MED12, and
BRD4 binding.
BRD4 binding sites derived from prostate cancer
cells do not enrich for SNPs associated with breast
cancer
To test the specificity of BRD4, MED12 and H3K27Ac
profiles in PC cells in identifying tissue-specific SNPs,
we performed a similar enrichment analysis for genetic
association with BC risk measured on the genotype array
content from the BCAC [31] (Fig. 2d). Enhancers de-
fined on the basis of BRD4 binding profile in PC cells
failed to enrich specifically for BC associated SNPs.
Whilst H3K27ac and MED12 together achieved some
enrichment of BC SNPs, the addition of BRD4 depleted
this enrichment entirely. Importantly, once again, ran-
domly pruning the SNPs did not alter the results of the
enrichment analysis (Additional file 22: Figure S4).
These results are in stark contrast to the analysis on PC
datasets in which inclusion of BRD4 enhanced enrich-
ment of low p-valued SNPs associated with PC, and sug-
gests a hierarchical determination of tissue-specificity,
based on the subsequential deposition of these epigen-
etic marks. Taken together, this indicates that BRD4
Fig. 1 Definition of enhancers using chromatin marks and generic epigenetic readers. UCSC genome browser snapshot of the kallikreins locus showing
enhancers identified in LNCaP based on MED12 binding information retrieved from Wang et al., (2012), and H3K27Ac profile retrieved from Hnisz et al.,
(2014) [12]; Enhancers identified in VCaP based on BRD4 binding and H3K27Ac retrieved from Asangani et al., (2014) [14]; and common enhancers in
prostate cancer (PC) identified selecting enhancers in LNCaP which also had BRD4 and acetylation signature according to the compendium of enhancers
in VCaP cells. In the locus shown here the long stretch of H3K27Ac includes also MED12 according to Wang et al., (2011) [23] and BRD4 binding sites. At
the bottom of the figure SNPs within these particular enhancers are indicated with the red line for SNPs found in the enhancers in LNCaP cells and PC
common enhancers, and with the blue line for SNPs found in the enhancer in VCaP cells. Independent tracks for the androgen receptor (AR) binding sites
in common in LNCaP and VCaP cells according to Massie et al., (2011) [22] re-analyzed for this study are also shown
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substantially contributes to prostate-specific SNP enrich-
ment within super-enhancers.
Of note, the genomic distribution of the BCAC SNP array
mirrored the genomic distribution of the SNP arrays used
for iCOGS with the majority of SNPs located within intronic
(48% and 57%, respectively) and intergenic (48% and 34%,
respectively) regions of the genome (Additional file 22: Fig-
ure S5) thus meaning that whilst the number of SNPs dif-
fered between the PC and BC studies, there was no genomic
distribution bias for imputed SNPs. The SNPs included
within the enhancers defined in this study reflected similar
distributions, with the only exception of SNPs lists derived
from LNCaP cells that were slightly biased toward intergenic
regions. Around 69% to 77% of the SNPs were located
within intergenic regions (data not shown).
Enrichment of SNPs associated with breast cancer in
regions bound by BRD4, marked by H3K27Ac in breast
cancer cells
Next, we sought to identify whether using BC-specific epigen-
etic profiles for the samemarkers derived from the BC cell line
MCF7, we would be able to repeat the same performance as
in the PC enrichment analysis. Therefore we retrieved
genome-wide profiles of H3K27Ac, ER, and BRD4 binding in
MCF7 [25], compiled a similar list of enhancers (Table 1 and
Additional file 22: Figure S6), and performed an enrichment
analysis of association with BC risk on the BCAC GWAS
(Fig. 2e and Additional file 22: Table S4). Information on
MED binding is not available for BC cell lines. However,
BRD4 binding information alone caused the strongest en-
richment of SNPs associated with BC (Additional file 22:
Table S5). These data confirm that BRD4 alone is an im-
portant enhancer and super-enhancer discriminant, which
binds disease-specific susceptibility loci in a tissue specific
fashion. Randomly pruning the SNPs involved, proved not
to alter the capacity of BRD4 of capturing disease-specific
associated SNPs (Additional file 22: Figure S7). Interest-
ingly, pruning the SNPs revealed that ER capability to cap-
ture disease associated SNPs in combination with other
epigenetic features was enhanced, possibly suggesting a
different contribution of ER and AR in breast and PC
pathogenesis, respectively.
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Fig. 2 Enrichment of SNPs lying within enhancers. Q-Q plots visualizing the p-value enrichment of sets of SNPs mapping within genomic intervals
identified as regions of putative enhancers or key transcription factor binding sites. The p-values describe the association of a specific SNP with
prostate (iCOGs in panel a & b; PRACTICAL in panel c) and breast cancer (BCAC in panel d & e). The genomic intervals represent regions bound
by MED12, BRD4 with a H3K27Ac modification in prostate cancer cell lines (LNCaP and VCaP), or in overlapping regions profiled for a combination
of the features in the prostate cancer (PC) cell-lines as indicated (a, c, d), intersected with AR binding sites (b), or regions found in MCF7 (e), as
indicated in the legends. (f) Q-Q plots visualizing the p-value enrichment of schizophrenia associated SNPs (PGC) lying within enhancers identified
in Schwann cells
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As counterproof, we tested whether BC epigenetic pro-
files caused any enrichment in iCOGS PC associations,
but no such enrichment was detected (Additional file 22:
Figure S8). These results are consistent with BRD4 bind-
ing being cell and tissue-specific [35]. Moreover, these re-
sults pinpoint the tissue-specificity of risk loci and hint
that BRD4 activity may be influenced by genetic variations
as it is for TFs [2].
Enrichment of risk SNPs associated with lung cancer and
psychiatric traits using H3K27Ac profiles, BRD4, and MED
binding sites derived from relevant cell lines
To understand whether the properties of BRD4 binding to
clinically relevant genetic risk loci is confined to PC and
BC only, or such selectivity can also be observed to other
diseases and traits, we retrieved binding information for
BRD4, MED1 and H3K27Ac profiles available for the lyn-
phoblastoid cell line H2171 derived from a metastatic site
in a LC patient [10] and from the malignant peripheral
nerve sheath tumor Schwann cells 90-8TL [36] (Add-
itional files 12, 13, 14, 15, 16, 17 and 18). To retrieve asso-
ciations of these epigenetic features with other phenotypes
we collected summary statistics for LC [32], Alzheimer’s
disease [33], schizophrenia [21], and bipolar disorder [20].
BRD4 binding information alone caused the strongest
enrichment of associations with LC, although combined
information for BRD4 and MED1 binding, also com-
bined with H3K27Ac profile failed to improve the en-
richment of low p-value SNPs (Additional file 22: Figure
S9a). We speculate that the LC cell line H2171 might
not reflect characteristics of the tissue of origin, as well
as the PC and BC cell lines. However, upon assessing
the enrichment using epigenetic features related to PC
cells for the same LC GWAS (Additional file 22: Figure
S9b), as expected, we detected none, confirming that
BRD4 binding information in H2171 retains some tis-
sue-specificity and capacity to enrich for LC tissue-spe-
cific risk SNPs.
Fig. 3 Circular plots of GWAS significant SNPs overlapping with putative super-enhancers. The outmost circles depict chromosome-wise
histograms showing p-values of SNP loci (LD r^2 < 0.2 within 1Mbase) representatives for SNPs in iCOGS (a), for SNPs in BCAC (b), and
for SNPs associated with schizophrenia according to PGC (c). GWAS-significant SNPs are labeled and the nearby genes are also indicated.
The inmost circle represents super-enhancers regions identified in prostate cancer cells (SE_PC_BRD4_MED12_H3K27Ac) (a), breast cancer
cells (SE_MCF7_BRD4) (b), and in Schwann cells (SE_Schwann_BRD4) (c) that were most enriched of low p-value SNPs
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Next, we applied our enrichment method to perform an in-
verse analysis in which we sought to understand whether any
association could be found between epigenetic features related
to Schwann cells (the only brain cells for which H3K27Ac
profile and BRD4 binding informationwere publicly available)
and three diseases affecting the brain. No enrichment for
SNPs associated with Alzheimer disease and bipolar disorder
was detected (Additional file 22: Figure S10a&b). However,
low p-valued SNPs associated with schizophrenia were highly
enriched within BRD4 binding sites (Fig. 2f). Interestingly
H3K27Ac profiles also enriched substantially for clinically
relevant SNPs associated with schizophrenia. These data sug-
gest that BRD4 activity in Schwann cells could potentially be
involved in the etiology of schizophrenia [37], and grant fur-
ther investigation on the molecular mechanism underlying
these findings.
Discussion
With the discovery of significant numbers of cancer genetic
risk loci through GWAS there is now a major focus on the
functional annotation of these loci to prioritize them for fur-
ther biological study. So far this annotation has been under-
taken Post-GWAS and has often employed classifiers of open
chromatin, for example DHS, as a primary annotation
followed by genome-wide binding maps for tissue-specific
transcription factors such as the AR for PC or the ER for BC,
while combining this information with H3K27Ac and open
chromatin in a tissue-specific manner [38]. In this study we
ask whether it is possible to use binding sites data and chro-
matinmarks upfront to enrich for genetic risk factors in a can-
cer type-specific manner. We show that an enhancer
signature comprising a number of factors but dominated by
BRD4 allows for the enrichment of PC-specific and BC-
specific genetic risk loci (Fig. 3a and b ). Interestingly, these
chromatin features have been previously reported to be char-
acteristic of super-enhancer-like profiles [10–12, 35]. We
found a strong degree of tissue-specificity, that is when pro-
files are derived from cell-lines associated with specific cancer
types such as the cancer of the breast and prostate, they be-
come far more effective at enriching for cancer-type specific
risk loci than other widely used cancer type-specific TFs such
as theAR, ER orDHSs alone.We also applied this enrichment
strategy to infer that BRD4 binding information may allow in
future for the upfront nomination of genomic-regions for
high-coverage sequencing in risk studies for schizophrenia
(Fig. 3c). Functional determination of the impact of risk SNPs
have been the priority of several consortia aiming to uncover
the effects on epigenetics mediated by clinically relevant risk
variants located in non-exonic regions [39]. Our study implies
a conserved and important relationship between enhancers
and cancer-associated risk loci, which is being pinpointed also
by recent work linking the effect of genetic variation to TFs
binding [2]. Our approach is the first one that implies an effect
of such genetic variations on the activity of generic epigenetic
Fig. 4 Tissue-specific super-enhancers usage and identification of clinically relevant genetic variations associated with diseases and traits. The
method for prioritization of clinically relevant SNPs is based on the identification of risk SNPs with GWAS significance that are associated with
BRD4 binding to chromatin, within tissue-specific super-enhancers rather transcription factors binding
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readers. This is also the first time that such epigenetic
readers have been evaluated as enrichment factors for
SNPs without prior filtering based on published p-values
for risk association.
We highlight the possibility that SNPs lying within super-
enhancers marked by BRD4 are more likely to be associated
with an increased susceptibility to BC, PC, and schizophrenia.
The expression of the genes regulated by enhancers identified
in these diseases could be altered by the presence of specific
SNPs lying therein (Additional file 22: Figure S11). This is a
concept that has recently been postulated for cancer muta-
tions occurring in a chromatin-specific context [40].
Conclusions
In conclusion we have discovered that BRD4-bound
super-enhancers provide a powerful tool for enriching
and prioritizing PC and BC genetic risk loci (Fig. 4),
and have shown that key TFs such as AR or ER, des-
pite being pivotal tissue-specific TFs, do not contrib-
ute to tissue-specific genetic risk enrichment more
than epigenetic factors. We propose to refine disease
specific risk loci enrichment with the identification of
potential binding of BRD4 combined with key MED
components and acetylation profiles. Our study will
promote the use of BRD4 for SNP annotation as the
genetic landscape for different diseases goes on
expanding.
Additional files
Additional file 1: SE_LNCaP_H3K27Ac. (XLS 84 kb)
Additional file 2: SE_LNCaP_MED12_H3K27Ac. (XLS 45 kb)
Additional file 3: SE_VCaP_H3K27Ac. (BED 344 kb)
Additional file 4 SE_VCaP_BRD4_H3K27Ac. (XLS 42 kb)
Additional file 5: SE_VCaP_BRD4. (XLS 945 kb)
Additional file 6: SE_PC_BRD4_MED12_H3K27Ac. (XLS 28 kb)
Additional file 7: SE_MCF7_H3K27Ac. (XLS 539 kb)
Additional file 8: SE_MCF7_BRD4_ER. (XLS 72 kb)
Additional file 9: SE_MCF7_H3K27Ac_ER. (XLS 87 kb)
Additional file 10: SE_MCF7_BRD4_H3K27Ac_ER. (XLS 54 kb)
Additional file 11: SE_MCF7_BRD4_H3K27Ac. (XLS 137 kb)
Additional file 12: SE_H2171_BRD4_MED1_H3K27Ac. (BED 53 kb)
Additional file 13: SE_H2171_BRD4. (BED 1857 kb)
Additional file 14: SE_H2171_H3K27Ac. (BED 88 kb)
Additional file 15: SE_H2171_MED1_H3K27Ac. (BED 53 kb)
Additional file 16: SE_Schwann_BRD4_H3K27Ac. (BED 153 kb)
Additional file 17: SE_Schwann_BRD4. (BED 916 kb)
Additional file 18: SE_Schwann_H3K27Ac. (BED 195 kb)
Additional file 19: DHS_consensus. (BED 3694 kb)
Additional file 20: DHS_encode. (BED 6397 kb)
Additional file 21: DHS_He. (BED 4673 kb)
Additional file 22: Including Supplementary Material such as
Supplementary Figures S1–S11, Supplementary Tables S1–S5,
and Supplementary References. (DOCX 2037 kb)
Abbreviations
AR: Androgen receptor; ARBSs: AR binding sites; BC: Breast cancer;
BCAC: Breast Cancer Association Consortium; BRD4: bromodomain
containing protein 4; ENCODE: Encyclopedia of DNA Elements; ER: Estrogen
receptor; GWAS: Genome-wide association studies; H3K27Ac: Acetylation
on Histone 3 lysine 27; iCOGS: Illumina array Collaborative Oncological
Gene-environment Study; MED1/MED12: Mediator complex subunit 1/12;
PC: Prostate cancer; PRACTICAL: Prostate Cancer Association Group to
Investigate Cancer Associated Alterations in the Genome; SNPs: Single
nucleotide polymorphisms
Acknowledgements
We thank the COGS, PRACTICAL, TRICL and BCAC consortia for access to
GWAS summary statistics data. Further details are provided below.
The PRACTICAL Consortium (http://practical.ccge.medschl.cam.ac.uk/):
Rosalind Eeles1,2, Doug Easton3, Zsofia Kote-Jarai1, Ali Amin Al Olama3, Sara
Benlloch3, Kenneth Muir4, Graham G. Giles5,6, Fredrik Wiklund7, Henrik
Gronberg7, Christopher A. Haiman8, Johanna Schleutker9,10, Maren
Weischer11, Ruth C. Travis12, David Neal13, Paul Pharoah14, Kay-Tee Khaw15,
Janet L. Stanford16,17, William J. Blot18, Stephen Thibodeau19, Christiane
Maier20,21, Adam S. Kibel22,23, Cezary Cybulski24, Lisa Cannon-Albright25,
Hermann Brenner26,27, Jong Park28, Radka Kaneva29, Jyotsna Batra30, Manuel
R. Teixeira 31, Hardev Pandha32
1The Institute of Cancer Research, London, SM2 5NG, UK, 2Royal Marsden
NHS Foundation Trust, London, SW3 6JJ, UK, 3Centre for Cancer Genetic
Epidemiology, Department of Public Health and Primary Care, University of
Cambridge, Strangeways Research Laboratory, Worts Causeway, Cambridge,
UK, 4University of Warwick, Coventry, UK, 5Cancer Epidemiology Centre,
Cancer Council Victoria, 615 St Kilda Road, Melbourne Victoria, Australia,
6Centre for Epidemiology and Biostatistics, Melbourne School of Population
and Global Health, The University of Melbourne, Victoria, Australia,
7Department of Medical Epidemiology and Biostatistics, Karolinska Institute,
Stockholm, Sweden, 8Department of Preventive Medicine, Keck School of
Medicine, University of Southern California/Norris Comprehensive Cancer
Center, Los Angeles, California, USA, 9Department of Medical Biochemistry
and Genetics, Institute of Biomedicine, Kiinamyllynkatu 10, FI-20014
University of Turku; and Tyks Microbiology and Genetics, Department of
Medical Genetics, Turku University Hospital, 10BioMediTech, 30014 University
of Tampere, Tampere, Finland, 11Department of Clinical Biochemistry, Herlev
Hospital, Copenhagen University Hospital, Herlev Ringvej 75, DK-2730 Herlev,
Denmark, 12Cancer Epidemiology Unit, Nuffield Department of Clinical
Medicine, University of Oxford, Oxford, UK, 13Surgical Oncology (Uro-
Oncology: S4), University of Cambridge, Box 279, Addenbrooke’s Hospital,
Hills Road, Cambridge, UK and Cancer Research UK Cambridge Research
Institute, Li Ka Shing Centre, Cambridge, UK, 14Centre for Cancer Genetic
Epidemiology, Department of Oncology, University of Cambridge,
Strangeways Research Laboratory, Worts Causeway, Cambridge, UK,
15Cambridge Institute of Public Health, University of Cambridge, Forvie Site,
Robinson Way, Cambridge CB2 0SR, 16Division of Public Health Sciences,
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA,
17Department of Epidemiology, School of Public Health, University of
Washington, Seattle, Washington, USA, 18International Epidemiology Institute,
1455 Research Blvd., Suite 550, Rockville, MD 20850, 19Mayo Clinic, Rochester,
Minnesota, USA, 20Department of Urology, University Hospital Ulm, Germany,
21Institute of Human Genetics University Hospital Ulm, Germany, 22Brigham
and Women's Hospital/Dana-Farber Cancer Institute, 45 Francis Street- ASB II-
3, Boston, MA 02115, 23Washington University, St Louis, Missouri,
24International Hereditary Cancer Center, Department of Genetics and
Pathology, Pomeranian Medical University, Szczecin, Poland, 25Division of
Genetic Epidemiology, Department of Medicine, University of Utah School of
Medicine, 26Division of Clinical Epidemiology and Aging Research & Division
of Preventive Oncology, German Cancer Research Center, Heidelberg
Germany, 27German Cancer Consortium (DKTK), German Cancer Research
Center (DKFZ), Heidelberg Germany, 28Division of Cancer Prevention and
Control, H. Lee Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, Florida,
USA, 29Molecular Medicine Center and Department of Medical Chemistry
and Biochemistry, Medical University - Sofia, 2 Zdrave St, 1431, Sofia, Bulgaria,
30Australian Prostate Cancer Research Centre-Qld, Institute of Health and
Biomedical Innovation and Schools of Life Science and Public Health,
Queensland University of Technology, Brisbane, Australia, 31Department of
Genetics, Portuguese Oncology Institute, Porto, Portugal and Biomedical
Zuber et al. BMC Genomics  (2017) 18:270 Page 9 of 11
Sciences Institute (ICBAS), Porto University, Porto, Portugal, 32The University
of Surrey, Guildford, Surrey, GU2 7XH, UK
COGS acknowledgement and funding: This study would not have been
possible without the contributions of the following: Per Hall (COGS); Douglas
F. Easton, Paul Pharoah, Kyriaki Michailidou, Manjeet K. Bolla, Qin Wang
(BCAC), Andrew Berchuck (OCAC), Rosalind A. Eeles, Douglas F. Easton, Ali
Amin Al Olama, Zsofia Kote-Jarai, Sara Benlloch (PRACTICAL), Georgia
Chenevix-Trench, Antonis Antoniou, Lesley McGuffog, Fergus Couch and Ken
Offit (CIMBA), Joe Dennis, Alison M. Dunning, Andrew Lee, and Ed Dicks,
Craig Luccarini and the staff of the Centre for Genetic Epidemiology
Laboratory, Javier Benitez, Anna Gonzalez-Neira and the staff of the CNIO
genotyping unit, Jacques Simard and Daniel C. Tessier, Francois Bacot, Daniel
Vincent, Sylvie LaBoissière and Frederic Robidoux and the staff of the McGill
University and Génome Québec Innovation Centre, Stig E. Bojesen, Sune F.
Nielsen, Borge G. Nordestgaard, and the staff of the Copenhagen DNA
laboratory, and Julie M. Cunningham, Sharon A. Windebank, Christopher A.
Hilker, Jeffrey Meyer and the staff of Mayo Clinic Genotyping Core Facility
Funding for the iCOGS infrastructure came from: the European Community's
Seventh Framework Programme under grant agreement n° 223175 (HEALTH-
F2-2009-223175) (COGS), Cancer Research UK (C1287/A10118, C1287/A
10710, C12292/A11174, C1281/A12014, C5047/A8384, C5047/A15007, C5047/
A10692, C8197/A16565), the National Institutes of Health (CA128978) and
Post-Cancer GWAS initiative (1U19 CA148537, 1U19 CA148065 and 1U19
CA148112 - the GAME-ON initiative), the Department of Defence (W81XWH-
10-1-0341), the Canadian Institutes of Health Research (CIHR) for the CIHR
Team in Familial Risks of Breast Cancer, Komen Foundation for the Cure, the
Breast Cancer Research Foundation, and the Ovarian Cancer Research Fund.
Breast Cancer Association Consortium (BCAC) (http://bcac.ccge.medschl.cam.ac.uk/)
BCAC Lead Investiagtors:
Douglas Easton, Ph.D1, Paul Pharoah, Ph.D2, Georgia Chenevix-Trench, Ph.D3,
Manjeet Humphreys1
1University of Cambridge, 2Cambridge Cancer Center, 3Queensland Institute
of Medical Research
Transdisciplinary Research in Cancer of the Lung (TRICL) Research Team:
Hung RJ1, Han Y2, Brennan P3, Bickeböller H4, Rosenberger A4, Houlston RS5,
Caporaso N6, Landi MT6, Heinrich J7, Risch A8, Wu X9, Ye Y9, Christiani DC10,11,
Amos CI2
1Lunenfeld-Tanenbaum Research Institute of Mount Sinai Hospital, Toronto,
Ontario, Canada, 2Department of Biomedical Data Science, Geisel School of
Medicine, Dartmouth College, Hanover, NH, 3Genetic Epidemiology Group,
International Agency for Research on Cancer (IARC), Lyon, France,
4Department of Genetic Epidemiology, University Medical Center, Georg-
August-University Göttingen, Göttingen, Germany, 5Division of Genetics and
Epidemiology, The Institute of Cancer Research, London, United Kingdom,
6Division of Cancer Epidemiology and Genetics, National Cancer, Institute,
National Institutes of Health, Bethesda, MD, USA, 7Helmholtz Centre Munich,
German Research Centre for Environmental Health, Institute of Epidemiology
I, Neuherberg, Germany, 8Department of Molecular Biology, University of
Salzburg, Salzburg, Austria, 9Department of Epidemiology, UT MD Anderson
Cancer Center, Houston, TX, 10Massachusetts General Hospital, Boston,
Massachusetts, 11Department of Environmental Health, Harvard School of
Public Health, Boston, Massachusetts
Funding
A.U. is supported by the South-East Norway Health Authorities (Helse Sor-Ost
grant ID 2014040) at the Oslo University Hospital, and the Norwegian Centre
for Molecular Medicine. I.G.M. is supported by funding from the Research
Council of Norway (RCN), South East Norway Health Authority (SENHA) and
the University of Oslo through the Centre for Molecular Medicine (Norway),
which is part of the Nordic EMBL (European Molecular Biology Laboratory)
partnership and also supported by Oslo University Hospitals. I.G.M. is also
supported by the Norwegian Cancer Society and by EU FP7 funding. I.G.M.
holds a visiting scientist position with Cancer Research UK through the
Cambridge Research Institute and a Senior Visiting Research Fellowship with
Cambridge University through the Department of Oncology. A.U. is funded
by the SENHA at the Oslo University Hospital. V. Z. is supported by the
Centre for Molecular Medicine (Norway) and together with A.W., F.B and
O.A.A. supported by the Norwegian Centre of Research in Mental Disorders
(NORMENT) with funding from the RCN, SENHA, Norwegian Health
Association and KG Jebsen Foundation. This work was supported by the
Kristian Gerhard Jebsen Foundation, Centre for Molecular Medicine Norway,
Research Council of Norway (213837, 223273), South-East Norway Health
Authorities (2013–123), National Institutes of Health (R01AG031224,
R01EB000790 and RC2DA29475). I.G.M. and group members participate in
the NIH Genetic Associations and Mechanisms in Oncology (GAME-ON): A
Network of Consortia for Post-Genome Wide Association (Post-GWA)
Research (prostate: 1U19CA148537-01).
This work was also supported by Cancer Research UK Grant C5047/A3354.
We would also like to thank the following for funding support: the Institute
of Cancer Research and the Everyman Campaign, the Prostate Cancer
Research Foundation, Prostate Research Campaign UK (now known as
Prostate Cancer UK), the National Cancer Research Network UK and the
National Cancer Research Institute (NCRI) UK. The ProtecT study is ongoing
and is funded by the Health Technology Assessment Programme (projects
96/20/06, 96/20/99). The ProtecT trial and its linked ProMPT and CAP
(Comparison Arm for ProtecT) studies are supported by Department of
Health, UK, Cancer Research UK grant number C522/A8649, Medical Research
Council (UK) grant number G0500966, ID 75466 and the NCRI, UK. The
epidemiological data for ProtecT were generated through funding from the
Southwest National Health Service Research and Development.
Availability of data and materials
The data supporting the results of this research paper are included within
this article and its additional supplementary files. Summary statistics from
the GWAS studies used in this manuscript are available through application
to the relevant consortia (PRACTICAL, BCAC, TRICL and iCOGS).
Authors’ contributions
IGM, AU and VZ conceived the study, performed data analysis and wrote the
manuscript. IGM helped the conceptual design of the study, the preparation
of the manuscript, and the interpretation of the results. FB and AW provided
scripts for random pruning and edited the manuscript, OAA edited the
manuscript. All authors read and approved the final manuscript.
Competing interests
The authors declare that they have no competing interests.
Consent of publication
Not applicable
Ethics approval and consent to participate
No patient samples were collected and analysed during this study. All GWAS
data were provided as summary statistics by the consortia acknowledged in
this study having been collected in accordance with ethical regulations in
the partner countries and as defined in original research publications by
such consortia.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Prostate Cancer Research Group, Centre for Molecular Medicine Norway
(NCMM), Nordic EMBL Partnership, Faculty of Medicine, University of Oslo,
Oslo, Norway. 2NORMENT, KG Jebsen Centre for Psychosis Research, Institute
of Clinical Medicine, University of Oslo, Oslo, Norway. 3Division of Mental
Health and Addiction, Oslo University Hospital, Oslo, Norway. 4European
Molecular Biology Laboratory, European Bioinformatics Institute, Wellcome
Trust Genome Campus, Hinxton, Cambridge, UK. 5Centre for Cancer Genetic
Epidemiology, University of Cambridge, Cambridge, UK. 6Department of
Molecular Oncology, Institute for Cancer Research, Oslo University Hospital,
Oslo, Norway. 7PCUK Movember Centre of Excellence, CCRCB, Queen’s
University, Belfast, UK.
Received: 3 March 2016 Accepted: 11 March 2017
References
1. Welter D, MacArthur J, Morales J, Burdett T, Hall P, Junkins H, Klemm A,
Flicek P, Manolio T, Hindorff L, et al. The NHGRI GWAS Catalog, a curated
Zuber et al. BMC Genomics  (2017) 18:270 Page 10 of 11
resource of SNP-trait associations. Nucleic acids research. 2014;42(Database
issue):D1001–1006.
2. Tehranchi AK, Myrthil M, Martin T, Hie BL, Golan D, Fraser HB. Pooled ChIP-
Seq Links Variation in Transcription Factor Binding to Complex Disease Risk.
Cell. 2016;165(3):730–41.
3. Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H,
Reynolds AP, Sandstrom R, Qu H, Brody J, et al. Systematic localization of
common disease-associated variation in regulatory DNA. Science (New York,
NY). 2012;337(6099):1190–5.
4. Coetzee SG, Shen HC, Hazelett DJ, Lawrenson K, Kuchenbaecker K, Tyrer J,
Rhie SK, Levanon K, Karst A, Drapkin R et al.: Cell Type Specific Enrichment
Of Risk Associated Regulatory Elements At Ovarian Cancer Susceptibility
Loci. Human molecular genetics. 2015;24(13):3595–607.
5. Paul DS, Soranzo N, Beck S. Functional interpretation of non-coding
sequence variation: concepts and challenges. Bioessays. 2014;36(2):191–9.
6. Ritchie GR, Dunham I, Zeggini E, Flicek P. Functional annotation of
noncoding sequence variants. Nat Methods. 2014;11(3):294–6.
7. Huang CN, Huang SP, Pao JB, Chang TY, Lan YH, Lu TL, Lee HZ, Juang SH,
Wu PP, Pu YS, et al. Genetic polymorphisms in androgen receptor-binding
sites predict survival in prostate cancer patients receiving androgen-
deprivation therapy. Ann Oncol. 2012;23(3):707–13.
8. Hazelett DJ, Rhie SK, Gaddis M, Yan C, Lakeland DL, Coetzee SG, Henderson
BE, Noushmehr H, Cozen W, Kote-Jarai Z, et al. Comprehensive functional
annotation of 77 prostate cancer risk loci. PLoS genetics. 2014;10(1):
e1004102.
9. Corradin O, Scacheri PC. Enhancer variants: evaluating functions in common
disease. Genome Med. 2014;6(10):85.
10. Loven J, Hoke HA, Lin CY, Lau A, Orlando DA, Vakoc CR, Bradner JE, Lee TI,
Young RA. Selective inhibition of tumor oncogenes by disruption of super-
enhancers. Cell. 2013;153(2):320–34.
11. Whyte WA, Orlando DA, Hnisz D, Abraham BJ, Lin CY, Kagey MH, Rahl PB,
Lee TI, Young RA. Master transcription factors and mediator establish super-
enhancers at key cell identity genes. Cell. 2013;153(2):307–19.
12. Hnisz D, Abraham BJ, Lee TI, Lau A, Saint-Andre V, Sigova AA, Hoke HA,
Young RA. Super-enhancers in the control of cell identity and disease. Cell.
2013;155(4):934–47.
13. Arshad Z, Smith J, Roberts M, Lee WH, Davies B, Bure K, Hollander GA,
Dopson S, Bountra C, Brindley D. Open Access Could Transform Drug
Discovery: A Case Study of JQ1. Expert opinion on drug discovery. 2016;
11(3):321–32.
14. Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J,
Wilder-Romans K, Dhanireddy S, Engelke C, et al. Therapeutic targeting of
BET bromodomain proteins in castration-resistant prostate cancer. Nature.
2014;510(7504):278–82.
15. Shaikhibrahim Z, Offermann A, Braun M, Menon R, Syring I, Nowak M,
Halbach R, Vogel W, Ruiz C, Zellweger T, et al. MED12 overexpression is a
frequent event in castration-resistant prostate cancer. Endocr Relat Cancer.
2014;21(4):663–75.
16. Liu G, Sprenger C, Wu PJ, Sun S, Uo T, Haugk K, Epilepsia KS, Plymate S.
MED1 mediates androgen receptor splice variant induced gene expression
in the absence of ligand. Oncotarget. 2015;6(1):288–304.
17. Andreassen OA, Zuber V, Thompson WK, Schork AJ, Bettella F, Djurovic
S, Desikan RS, Mills IG, Dale AM. Shared common variants in prostate
cancer and blood lipids. International journal of epidemiology. 2014;
43(4):1205–14.
18. Schork AJ, Thompson WK, Pham P, Torkamani A, Roddey JC, Sullivan PF,
Kelsoe JR, O'Donovan MC, Furberg H, Schork NJ, et al. All SNPs Are Not
Created Equal: Genome-Wide Association Studies Reveal a Consistent
Pattern of Enrichment among Functionally Annotated SNPs. PLoS genetics.
2013;9(4):e1003449.
19. Whitington T, Gao P, Song W, Ross-Adams H, Lamb AD, Yang Y, Svezia I,
Klevebring D, Mills IG, Karlsson R, et al. Gene regulatory mechanisms
underpinning prostate cancer susceptibility. Nature genetics. 2016;48(4):
387–97.
20. Psychiatric GWAS Consortium Bipolar Disorder Working Group. Large-scale
genome-wide association analysis of bipolar disorder identifies a new
susceptibility locus near ODZ4. Nature genetics 2011, 43(10):977–983.
21. Hoefer J, Kern J, Ofer P, Eder IE, Schäfer G, Dietrich D, Kristiansen G, Geley S,
Rainer J, Gunsilius E, et al. SOCS2 correlates with malignancy and exerts
growth-promoting effects in prostate cancer. Endocr Relat Cancer. 2014;
21(2):175–87.
22. Massie CE, Lynch A, Ramos-Montoya A, Boren J, Stark R, Fazli L, Warren A,
Scott H, Madhu B, Sharma N, et al. The androgen receptor fuels prostate
cancer by regulating central metabolism and biosynthesis. The EMBO
journal. 2011;30(13):2719–33.
23. Wang D, Garcia-Bassets I, Benner C, Li W, Su X, Zhou Y, Qiu J, Liu W,
Kaikkonen MU, Ohgi KA, et al. Reprogramming transcription by distinct
classes of enhancers functionally defined by eRNA. Nature. 2011;474(7351):
390–4.
24. Khan A, Zhang X. dbSUPER: a database of super-enhancers in mouse and
human genome. Nucleic acids research. 2016;44(D1):D164–171.
25. Nagarajan S, Hossan T, Alawi M, Najafova Z, Indenbirken D, Bedi U,
Taipaleenmaki H, Ben-Batalla I, Scheller M, Loges S, et al.
Bromodomain protein BRD4 is required for estrogen receptor-
dependent enhancer activation and gene transcription. Cell Rep.
2014;8(2):460–9.
26. Theodorou V, Stark R, Menon S, Carroll JS. GATA3 acts upstream of FOXA1
in mediating ESR1 binding by shaping enhancer accessibility. Genome
research. 2013;23(1):12–22.
27. Liu T, Ortiz JA, Taing L, Meyer CA, Lee B, Zhang Y, Shin H, Wong SS, Ma J,
Lei Y, et al. Cistrome: an integrative platform for transcriptional regulation
studies. Genome biology. 2011;12(8):R83.
28. He HH, Meyer CA, Chen MW, Jordan VC, Brown M, Liu XS. Differential DNase
I hypersensitivity reveals factor-dependent chromatin dynamics. Genome
research. 2012;22(6):1015–25.
29. Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA,
Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J, Jugurnauth-Little S, et
al. Identification of 23 new prostate cancer susceptibility loci using the
iCOGS custom genotyping array. Nature genetics. 2013;45(4):385–91.
391e381-382.
30. Eeles RA, Kote-Jarai Z, Giles GG, Olama AA, Guy M, Jugurnauth SK,
Mulholland S, Leongamornlert DA, Edwards SM, Morrison J, et al. Multiple
newly identified loci associated with prostate cancer susceptibility. Nature
genetics. 2008;40(3):316–21.
31. Michailidou K, Hall P, Gonzalez-Neira A, Ghoussaini M, Dennis J, Milne RL,
Schmidt MK, Chang-Claude J, Bojesen SE, Bolla MK, et al. Large-scale
genotyping identifies 41 new loci associated with breast cancer risk.
Nature genetics. 2013;45(4):353–61. 361e351-352.
32. Timofeeva MN, Hung RJ, Rafnar T, Christiani DC, Field JK, Bickeboller H, Risch
A, McKay JD, Wang Y, Dai J, et al. Influence of common genetic variation on
lung cancer risk: meta-analysis of 14 900 cases and 29 485 controls. Human
molecular genetics. 2012;21(22):4980–95.
33. Lambert JC, Ibrahim-Verbaas CA, Harold D, Naj AC, Sims R, Bellenguez C,
DeStafano AL, Bis JC, Beecham GW, Grenier-Boley B, et al. Meta-analysis
of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's
disease. Nature genetics. 2013;45(12):1452–8.
34. Taatjes DJ. The human Mediator complex: a versatile, genome-wide
regulator of transcription. Trends Biochem Sci. 2010;35(6):315–22.
35. Heinz S, Romanoski CE, Benner C, Glass CK. The selection and function of
cell type-specific enhancers. Nature reviews Molecular cell biology. 2015;
16(3):144–54.
36. De Raedt T, Beert E, Pasmant E, Luscan A, Brems H, Ortonne N, Helin K,
Hornick JL, Mautner V, Kehrer-Sawatzki H, et al. PRC2 loss amplifies Ras-
driven transcription and confers sensitivity to BRD4-based therapies. Nature.
2014;514(7521):247–51.
37. Weickert CS, Weickert TW. What's Hot in Schizophrenia Research? The
Psychiatric clinics of North America. 2016;39(2):343–51.
38. Gusev A, Shi H, Kichaev G, Pomerantz M, Li F, Long HW, Ingles SA, Kittles
RA, Strom SS, Rybicki BA, et al. Atlas of prostate cancer heritability in
European and African-American men pinpoints tissue-specific regulation.
Nature communications. 2016;7:10979.
39. Freedman ML, Monteiro AN, Gayther SA, Coetzee GA, Risch A, Plass C,
Casey G, De Biasi M, Carlson C, Duggan D, et al. Principles for the post-
GWAS functional characterization of cancer risk loci. Nature genetics. 2011;
43(6):513–8.
40. Polak P, Karlic R, Koren A, Thurman R, Sandstrom R, Lawrence MS, Reynolds A,
Rynes E, Vlahovicek K, Stamatoyannopoulos JA, et al. Cell-of-origin chromatin
organization shapes the mutational landscape of cancer. Nature. 2015;
518(7539):360–4.
Zuber et al. BMC Genomics  (2017) 18:270 Page 11 of 11
